3SBio Inc (1530)

Hong Kong
6.64
-0.22(-3.21%)
  • Volume:
    8,125,000
  • Bid/Ask:
    6.62/6.64
  • Day's Range:
    6.60 - 6.87

1530 Overview

Prev. Close
6.86
Day's Range
6.6-6.87
Revenue
7.32B
Open
6.78
52 wk Range
6.16-12.3
EPS
0.45
Volume
8,125,000
Market Cap
16.75B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
9,021,577
P/E Ratio
13.61
Beta
0.97
1-Year Change
-5.38%
Shares Outstanding
2,522,355,499
Next Earnings Date
Mar 28, 2022
What is your sentiment on 3SBio Inc?
or
Market is currently closed. Voting is open during market hours.

3SBio Inc Company Profile

Employees
5232
Market
Hong Kong

3SBio Inc. researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and INV. The company was founded in 1993 and is headquartered in Shenyang, the People’s Republic of China.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryBuyStrong SellStrong SellStrong SellStrong Sell
  • JPM Axes 3SBIO TP to $10; Rated Overweight
    0
    • Macquarie Adds 3SBIO TP to $13.08; Rated ***Outperform***
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.